Kornimate/medical-research-clean huggingface dataset:
liver embolization approaches for tumor management

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Metastatic Colon Cancer; Metastatic Cancer; Metastatic Gastric Cancer; Primary Liver Cancer; Metastatic Pancreatic Cancer

Summary: the goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors. the main aim is to evaluate progression free survival following embolization in this study population or evaluate residual hepatic volume in cases in which these techniques are used to induce liver regeneration. this study is an observational registry - all patients will follow their normal therapeutic and treatment scheme as per clinical practice, without any additional intervention.


Eligibility criteria:
inclusion criteria: * ≥ 18 yoa * patients with patients with primary or secondary liver disease not amenable for surgery or ablation * patients with primary or secondary liver tumors candidates for major surgery prior to induction of hypertrophy * able and willing to sign informed consent exclusion criteria: * pregnant women * patients with uncorrectable coagulopathy * diffuse extrahepatic disease * for lobar tace and tare - presence of bilodigestive shunt * for tare - \>20% hepatopulmonary shunt

Keywords: embolization, tae, tace, tare, pve, hve
evaluation of anti-pd-1 therapy by monitoring t cell responses in melanoma, lung and other cancer types

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Lung Carcinoma; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8

Summary: this study explores the role of t cells in monitoring disease status and response during anti-pd-1/pd-l1 treatment in patients with melanoma, lung and other cancer types. measuring levels of specific targets such as bim and soluble pd-l1 during therapy may help track treatment resistance and clinical outcomes. this information may also help researchers determine why some people with melanoma, lung and other cancer types respond to pd-1/pd-l1 treatment and others do not.

primary objectives: i. establish the role of bim for monitoring disease status during anti-pd-1 therapy. ii. identify the mechanisms of resistance to anti-pd-1 blockade. iii. quantify and modulate levels of nkg7 messenger ribonucleic acid (mrna) in cd8+ t cells. outline: this is an observational study. patients undergo blood sample collection throughout the study. patients also undergo optional stool sample collection and have their medical records reviewed on study. in addition, patients provide previously-collected tissue sample, if available.

Eligibility criteria:
inclusion criteria: * are 18 years of age or older * have histologic evidence of locally or regionally advanced or stage iv malignancy * are considered appropriate for starting therapy with anti-pd-1/anti-pd-l1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ici) is allowed) * have an understanding of the protocol and its requirements, risks, and discomforts * are willing to undergo peripheral blood collection at the time points mentioned in the protocol * are able and willing to sign an informed consent exclusion criteria: * inability on the part of the patient to understand the informed consent or be compliant with the protocol * patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-pd-1/anti-pd-l1 agent as mentioned above) * patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception
self-efficacy enhancement and exposure therapy

Conditions: Specific Phobia

Summary: self-efficacy refers to the perceived belief to cope effectively, by personal efforts, with challenging situations and problems (bandura, 1977). basic research has shown that increases in perceived self-efficacy can enhance the extinction of fear (zlomuzica et al., 2015). this study is aimed at translating these findings into a useful clinical application to augment exposure-based treatment outcome.

in this study, the effects of self-efficacy enhancement on treatment outcome in patients with height phobia will be investigated. participants will be randomly assigned to one of the following conditions: i) virtual reality exposure + self-efficacy enhancement; ii) virtual reality exposure + control intervention; iii) virtual reality exposure only. the amount of exposure is identical across groups (i.e. maximum of 1 hour of exposure). the self-efficacy and the control intervention involve the retrieval of the exposure session with or without a focus on personal mastery experiences/achievements, respectively. treatment-induced changes as well as the effects of self-efficacy enhancement will be measured on the subjective level (i.e. in-vivo behavioral approach tests, bats; church tower), physiological level (heart rate during the bats), and subjective level (subjective fear during the bats as well as height-phobia related questionnaires) at each of the three assessments (i.e. pretreatment, after which the exposure will conducted on the same day, i.e. day 1; posttreatment, which is scheduled approximately 2-3 days after exposure, and follow-up assessment, which will take place 1-month after exposure).

Eligibility criteria:
inclusion criteria: * specific phobia (acrophobia) * normal or corrected vision exclusion criteria: * somatic or neurological disease * personality disorder * bipolar disorder * acute drug- or alcoholabuse * pharmacological treatment within the past 4 weeks * mental retardation * any schizophrenic disease

Keywords: specific phobia height phobia exposure virtual reality extinction self-efficacy
taping for children with and without movement clumsiness

Conditions: Developmental Coordination Disorder

Summary: to investigate the effects of k tape on walking pattern, muscle activity and motor performance in children with and without developmental coordination disorder (dcd).


Eligibility criteria:
inclusion criteria: * children with dcd and typically developing children will need to score \ 25 percentile, respectively, on mabc-2 * study in mainstream schools * no intellectual disabilities exclusion criteria: * subjects who are receiving regular treatments * demonstrate excessive disruptive behaviour * unable to follow instructions * any diagnosis of neurological, musculoskeletal or cognitive disorder that affects test performance
effects of pcsk-9 inhibitor treatment prior to undergoing primary percutaneous coronary intervention in patients with st-segment elevation myocardial infarction

Conditions: STEMI

Summary: acute st-segment elevation myocardial infarction (stemi) is a common manifestation of cardiovascular emergencies. percutaneous coronary intervention (pci) and guideline-recommended pharmacotherapy have reduced mortality rates associated with stemi, but the incidence of recurrent ischemic events, particularly early ischemic events, remains high. current research suggests that low-density lipoprotein cholesterol (ldl-c) levels not meeting guideline-recommended levels and inflammation are closely related to early recurrent ischemic events. evolocumab, a proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitor, rapidly and effectively reduces ldl-c levels and suppresses inflammation. long-term use in patients with acute coronary syndromes can reverse atherosclerosis and improve prognosis. however, data on its use in stemi patients are limited, particularly regarding the cardioprotective effects of preoperative administration of 420mg evolocumab subcutaneous injection. this study aims to evaluate the effects of administering evolocumab 420mg before emergency pci on lipid profiles, inflammatory markers, myocardial injury, and short-term prognosis in stemi patients through a single-center, randomized, open-label study. it aims to provide theoretical evidence for further reducing the risk of recurrent cardiovascular events in stemi and identifying more optimized treatment strategies.


Eligibility criteria:
inclusion criteria: * all patients are selected from the cardiology department of beijing luhe hospital and have undergone direct pci treatment for stemi. * stemi patients must meet the following criteria: 1. chest pain duration ≥ 30 minutes, with st-segment elevation ≥ 0.1 mv in adjacent two leads on the electrocardiogram. 2. onset within 24 hours. 3. aged between 18 and 80 years. 4. signed informed consent form. exclusion criteria: * hemodynamically unstable or killip grade ≥ 2. * severe renal insufficiency: glomerular filtration rate \< 30 ml/min/1.73m\^2. * active liver disease or liver dysfunction: ast or alt levels \> 3 times the upper limit of normal. * known allergy to any drug used in the study. * previous or planned use of pcsk9 inhibitors. * suspected stress cardiomyopathy or acute pericarditis. * malignant tumors requiring treatment or other severe systemic diseases. * pregnancy or breastfeeding

Keywords: evolocumab stemi ldl-c
acorai machine learning generalization (mlg) study

Conditions: Heart Failure

Summary: acorai is developing a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters in patients with suspected or confirmed heart failure, and/or pulmonary hypertension, who require hemodynamic assessment. the device will be intended as a companion test or clinical decision support tool to be used and interpreted by qualified healthcare professionals to aid standard-of-care clinical assessment in identifying hemodynamic congestion and supporting personalized treatment of heart failure and pulmonary congestion. this study is part of the development of a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters. it will be conducted to collect the data needed to train the machine learning models retrospectively.


Eligibility criteria:
inclusion criteria: * subject is, at least, 18 years of age at the time of screening visit. * subject is willing and physically able to comply with the specified evaluations as per the clinical investigation plan, as assessed by the investigator. * subject is referred for invasive hemodynamic assessment with right heart cardiac catheterization. * patient has provided written informed consent using the ethics committee/ institutional review board approved consent form. exclusion criteria: * discretionary exclusion when, in the opinion of the investigator, the inclusion of a potential subject is not in their best interest or not in the interest of compliant performance of the clinical investigation. * subjects who are pregnant are excluded in the us
midline restoration after hybrid hernia repair surgery (hydra)

Conditions: Incisional Hernia of Midline of Abdomen

Summary: the goal of this observational study is to learn about the functioning of the abdominal wall in patients who underwent hybrid (open- and laparoscopic) incisional hernia repair. the main objective is to assess the anatomical restoration and function of the linea alba one year after surgery by ultrasonography and mean peak torque during trunk flexion using a biodex machine.

rationale: abdominal wall functioning has been reported to be higher in patients that underwent open incisional hernia repair compared to laparoscopic incisional hernia repair. with the use of a recently developed hybrid approach, we aim for a functional anatomical restoration of the linea alba while also achieving the technical advantages of the hybrid approach. objective: the main objective is to asses functional anatomical restoration of the linea alba through functioning in mean peak torque, and ultrasound examination. study design: multicentre prospective cohort study. study population: adult patients with a midline incisional hernia ≥4 cm and ≤10 cm. intervention: not applicable. main study parameters/endpoints: the primary objective of this study is to assess anatomical restoration and function of the linea alba one year after surgery by ultrasonography and measuring the mean peak torque during trunk flexion using a biodex(trademark) machine. nature and extent of the burden and risks associated with participation, benefit and group relatedness: no risk is associated with participation other than known complications for incisional hernia repair. hydra is part of standard care in the alrijne hospital, and the technique has previously been published. the mesh used in this study is being used on a world-wide scale. we do not expect additional risks with this study. as participants have to visit the erasmus medical center (erasmus mc) an additional three times and have to fill in additional questionnaires, there is a burden for enrolled patients.

Eligibility criteria:
inclusion criteria: * 18 years or older * scheduled for elective hydra-surgery * midline incisional hernia larger than 4 centimetres in mean width * sufficient knowledge of the dutch language to be able to understand and fill in the questionnaires * signed informed consent form by patient exclusion criteria: * pregnant at inclusion * inclusion in other trials with interference of the primary and secondary endpoints * american society of anesthesiologists classification (asa classification) \> 3 * hernia defect larger than 10 centimetres in mean width * incarcerated hernias or emergency procedure * unable to perform a trunk flexion * incapacitated patients

Keywords: incisional hernia repair hybrid
study of the tearcare system in dry eye disease

Conditions: Dry Eye

Summary: this study is being conducted to evaluate the short-term (1 month) safety and effectiveness of a single tearcare procedure to treat adult patients with dry eye disease. note: all sites have been selected for this study.


Eligibility criteria:
inclusion criteria: * diagnosed with dry eye disease * signs and symptoms of dry eye disease * best corrected visual acuity 20/100 or better * willing and able to comply with study procedures * willing and able to provide consent exclusion criteria: * active ocular infection or inflammation * history of eyelid, conjunctiva or corneal surgery within the past year. * recent office-based dry eye treatment, punctal occlusion or punctal plug placement * contact lens wearer * significant ocular surface or eyelid abnormalities, recent ocular trauma * certain corneal surface abnormalities * use of medications for treatment of dry eye or medications that cause dry eye * systemic disease that results in dry eye
propofol or midazolam for sedation and early extubation following coronary artery bypass graft surgery

Conditions: Coronary Artery Disease

Summary: propofol and midazolam are used frequently as sedating agents among patients who undergo coronary artery bypass graft surgery but no study in pakistan has been done to compare their effectiveness aiming early extubation.

propofol is an intra lipid and alkali phenol chemically it is unrelated to sedative agents or anaesthetic. midazolam is a banzodiazepen. most of its properties are similar to diazepam. it is a common practice to use sedatives to provide comfort and decrease "ventilator-asynchrony" in critically ill patients that may require prolonged invasive mechanical ventilation. the other reason to employ sedatives is to reduce the anxiety associated with the inaviseve procedures routinely conducted in the icu.

Eligibility criteria:
inclusion criteria: * patients of american society of anesthesiologists (asa) iii who were selected for coronary artery bypass graft surgery. exclusion criteria: * history of any psychiatric disease. * using antidepressants * alcohol abusers * obese * pregnant women

Keywords: coronary artery bypass graft midazolam propofol
effectiveness & safety of neofitoroid® in hemorrhoidal disease

Conditions: Hemorrhoids

Summary: evaluation of the effect and safety of neofitoroid® in reducing symptoms in patients with hemorrhoidal disease.

evaluation of the effect and safety of neofitoroid® in relieving discomfort symptom after 10 days of treatment compared to baseline (pretreatment). the study duration per patient is 31 days (visit 1 + 10 days treatment + 20 days follow-up).

Eligibility criteria:
inclusion criteria: 1. patients of both sexes ≥ 18 years . 2. diagnosis of hemorrhoidal disease of grade i or ii, non thrombosed, according to goligher's classification performed by anoscopy/rectoscopy at screening. 3. patient is not expected to require non-pharmacological (as sclerotherapy, rubber band ligation, infrared coagulation, radiofrequency ablation, cryotherapy) or surgical treatment in the 31 days post enrollment . 4. discomfort score related to the hemorrhoidal disease ≥ 30 measured through a 0-100 visual analog scale vas (from "no symptoms" to "overwhelming symptoms") at screening. 5. women of childbearing potential undergone a negative pregnancy test. 6. informed consent documentation signed and dated confirming that the patient has been adequately informed of all aspects related to his/her participation in the clinical study and is willing to participate. exclusion criteria: 1. patients with gastrointestinal disease like inflammatory bowel disease, celiac disease, colo-rectal cancer, perianal/fistulizing disease). 2. other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and/or that, in the judgment of the investigator, would make the subject inappropriate for entry into this study. 3. patients with active cancer. 4. tubercolosis , mycosis, herpes symplex, virologic disease with anal or perianal skin localization. 5. presence of physical and/or mental disability that reduces the ability to take medicines as expected. 6. concomitant abuse of drugs or alcohol. 7. no adequate reliability or presence of conditions that may result in non-compliance / adherence of the patient to the protocol. 8. subjects with known or suspected allergy to plants of helichrysum family, aloe vera, ruscus, hypericum, jojoba oil, shea butter, essential oils of: melaleuca, cypress and peppermint. 9. subjects with known or suspected allergy to ingredients such as: glicerilstearato, caprylic / capric, sucrose distearate, sucrose stearate, cetearyl alcohol, vegetable glycerin, triidrossistearina, vegetable oils, hydrogenated vegetable oils, candelilla wax, xanthan gum, citric acid, tocopherols, sodium silicate, benzyl alcohol, potassium sorbate, sodium dehydroacetate, sunflower oil. 10. subjects with the presence of alarm symptoms (weight loss, lack of appetite). 11. prior use of other topical ointment for the treatment of haemorrhoid within 14 days before enrollment. 12. pregnant and/or breastfeeding patients. 13. participation in interventional research studies of investigational medicinal or device products (ongoing or terminated less than 30 days before screening).
nit-occlud pda phase ii sentinel trial

Conditions: Ductus Arteriosus, Patent

Summary: the purpose of this study is to evaluate the safety and efficacy of the nit-occlud -pda occlusion system for transcatheter closure of pda with minimum angiographic diameter less than 4 mm, and to compare one year safety and efficacy outcomes with recommended opcs.

the purpose of this clinical investigation is to evaluate whether transcatheter occlusion of pdas with a minimum vessel diameter of 4 mm or smaller, by means of permanent implantation of the nit-occlud spiral coil for pda occlusion, is safe and effective. the device used for this purpose is a set of two items named "nit-occlud - pda occlusion system": * nit-occlud coils, 2 types: flexible (3 sizes) and medium (3 sizes) * introducer sheath, f4 or f5 85cm. the intended use of the device is the percutaneous, transluminal closure of pda with an internal diameter or 4mm and smaller in patients who comply with the selection criteria. the investigation will continue until the sponsor receives fda approval for commercial distribution and implantation of the system, or until the project is terminated by the sponsor or by the investigators. the objectives of this study are: 1. to determine the safety of the spiral coil by monitoring and reporting deaths and adverse events associated with the device and device placement. 2. to determine the effectiveness of the spiral coil by evaluating clinical and echocardiographic occlusion rates.

Eligibility criteria:
inclusion criteria: * pda with 4 mm or smaller minimum diameter by color doppler * patent weight \> 5 kg, age 6 months to 21 years (patients older than 21 years may have device implant and be included in a study registry.) * previous treatment by surgery or nit-occlud device with residual pda noted at least 6 months after the procedure * angiographic minimum pda diameter (d1) less than 4 mm. (patients with angiographic diameters larger than 4 mm and smaller or equal to 5 mm may have device implant and be included in a study registry.) exclusion criteria: * associated cardiac anomalies requiring surgery * known bleeding or blood clotting disorders * ongoing febrile illness * pregnancy * pulmonary hypertension/increased pulmonary vascular resistance (\>5 wood units) * known hypersensitivity to contrast medium

Keywords: transcatheter occlusion of patent ductus arteriosus
effectiveness of combination of arimidex and nolvadex in adjuvant therapy of breast carcinoma in postmenopausal women.

Conditions: Breast Cancer

Summary: the purpose of this study is to determine the efficacy and tolerability of 3 years treatment with anastrozole after a prior 2 years' treatment with tamoxifen versus 5 years treatment with tamoxifen in postmenopausal women with early breast cancer


Eligibility criteria:
inclusion criteria: * signed informed consent, * post-menopausal women ≤75 years, * histologically confirmed invasive breast carcinoma (no distant metastases), * positive hormone receptor status, * continuous 2-year adjuvant tamoxifen therapy 20 mg/30 mg with 4 weeks after primary surgery exclusion criteria: * menopause status maintained by medication, * pre-operative chemotherapy or hormone therapy or radiation therapy, * relapse or second carcinoma or previous cancerous disease, * breast carcinoma in situ, * simultaneous carcinoma of the opposite side or secondary breast, * 10 or more tumour-infiltrated lymph nodes. * serious accompanying diseases

Keywords: early breast cancer